Insugen 50/50 Injection 100IU/ml is a biphasic insulin formulation containing 50% insulin isophane (NPH insulin) and 50% human insulin, designed for the management of diabetes mellitus requiring insulin therapy. This combination provides both intermediate-acting and short-acting insulin effects, facilitating improved glycemic control by addressing both basal and prandial insulin requirements. Insulin isophane acts as an intermediate-acting insulin, offering sustained glucose-lowering activity, while human insulin provides rapid onset to manage postprandial glucose excursions. This preparation is indicated for patients with type 1 diabetes mellitus and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone are insufficient to achieve adequate glycemic control. Insugen 50/50 should be administered subcutaneously, with dosage individualized based on patient’s metabolic needs, blood glucose monitoring, and glycemic targets. Proper injection technique, rotation of injection sites, and adherence to prescribed dosing schedules are essential to optimize therapeutic outcomes and minimize the risk of hypoglycemia. Regular monitoring of blood glucose and periodic assessment of HbA1c levels are recommended to evaluate treatment efficacy. Patients should be educated regarding signs of hypoglycemia and appropriate corrective measures. Storage conditions require refrigeration between 2°C and 8°C, avoiding freezing and exposure to direct heat or light.